We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Without prescription

30 July 2019 By Dasha Afanasieva

The Strepsils maker failed to grow in the second quarter and cut a 2019 revenue growth goal to 2-3%. Even that looks tough given hard-to-fix issues in its health business such as baby food. Incoming CEO Laxman Narasimhan must overhaul its ailing healthcare unit before a breakup.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)